BridgeMD
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Pancreatic Cancer
EU CTIS ID: 2023-510208-39-00
What this study is testing
To assess the accuracy of 18F-FAPI-74 PET/CT in detection of local lymph node metastasis in patient level in patients with primary pancreatic cancer.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Primary or recurrent pancreatic cancer
- Suspected primary or recurrent pancreatic cancer
- Male or female aged 18-85 years
- WHO performance score 0-2
- Study subject signs informed consent form after receiving written information
You likely can't join if
- Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included
- Study subject is not able to understand the purpose of the study
- Medical conditions prohibiting whole-body PET/CT imaging
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.